Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tonix Pharmaceuticals Holding (TNXP) Cash & Equivalents (2023 - 2025)

Tonix Pharmaceuticals Holding (TNXP) has 3 years of Cash & Equivalents data on record, last reported at $97.6 million in Q3 2025.

  • For Q3 2025, Cash & Equivalents rose 245.69% year-over-year to $97.6 million; the TTM value through Sep 2025 reached $97.6 million, up 245.69%, while the annual FY2024 figure was $98.8 million, 295.93% up from the prior year.
  • Cash & Equivalents reached $97.6 million in Q3 2025 per TNXP's latest filing, down from $101.5 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $131.7 million in Q1 2025 and bottomed at $4.2 million in Q2 2024.
  • Average Cash & Equivalents over 3 years is $54.4 million, with a median of $28.2 million recorded in 2024.
  • Peak YoY movement for Cash & Equivalents: crashed 90.21% in 2024, then soared 2342.25% in 2025.
  • A 3-year view of Cash & Equivalents shows it stood at $24.9 million in 2023, then soared by 295.93% to $98.8 million in 2024, then decreased by 1.19% to $97.6 million in 2025.
  • Per Business Quant database, its latest 3 readings for Cash & Equivalents were $97.6 million in Q3 2025, $101.5 million in Q2 2025, and $131.7 million in Q1 2025.